Gut Liver.  2019 Sep;13(5):541-548. 10.5009/gnl18129.

Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease

• Choi SY
• Kang B
• Choe YH

• KMID: 2458511
• DOI: http://doi.org/10.5009/gnl18129

Abstract

BACKGROUND/AIMS
Infliximab (IFX) often loses its therapeutic effect in initial responders with inflammatory bowel disease (IBD) over time. Low serum IFX trough levels (TLs) are linked to poor clinical response and outcomes. Maintenance of optimal therapeutic IFX concentrations is important for sustaining response and achieving good clinical outcomes. Measurement of serum IFX TLs is helpful for determining a further proper therapeutic plan. However, adequate therapeutic IFX TLs in pediatric IBD is uncertain. We aimed to identify the cutoff values for IFX TLs associated with laboratory response to IFX maintenance therapy.
METHODS
Patients with pediatric IBD who had received IFX infusions between December 2008 and March 2015 at Samsung Medical Center were retrospectively investigated. We analyzed 239 blood samples that were collected from 103 pediatric patients. We measured IFX TLs at induction (6 and 14 weeks) and during maintenance therapy (>22 weeks, 8 weeks interval) by fluid-phase radioimmunoassays.
RESULTS
A significant association was found between the erythrocyte sedimentation rate (ESR) and IFX TLs during maintenance (correlation coefficient, −0.11; p=0.0005). A cutoff value of 18 mm/hr for ESR was used to define higher levels. Receiver operating characteristic analysis identified optimal cutoff values: IFX TL >1.58 μg/mL (sensitivity 82% and specificity 73%).
CONCLUSIONS
Cutoff values are considered a prerequisite for further investigating the clinical usefulness of measurements of IFX in patients maintained with IFX treatment.

Keyword

Infliximab; Drug monitoring; Pediatric inflammatory bowel disease

MeSH Terms

Blood Sedimentation
Drug Monitoring
Humans
Inflammatory Bowel Diseases*
Infliximab*
Radioimmunoassay
Retrospective Studies
ROC Curve
Sensitivity and Specificity
Infliximab